PMC:7696151 / 75601-75869 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"2179","span":{"begin":64,"end":67},"obj":"Chemical"},{"id":"2180","span":{"begin":91,"end":101},"obj":"Chemical"},{"id":"2198","span":{"begin":147,"end":172},"obj":"Disease"},{"id":"2199","span":{"begin":191,"end":196},"obj":"Disease"},{"id":"2200","span":{"begin":209,"end":215},"obj":"Disease"},{"id":"2201","span":{"begin":227,"end":231},"obj":"Disease"},{"id":"2261","span":{"begin":242,"end":248},"obj":"Disease"}],"attributes":[{"id":"A2179","pred":"tao:has_database_id","subj":"2179","obj":"MESH:D006886"},{"id":"A2180","pred":"tao:has_database_id","subj":"2180","obj":"MESH:C560077"},{"id":"A2198","pred":"tao:has_database_id","subj":"2198","obj":"MESH:D051437"},{"id":"A2199","pred":"tao:has_database_id","subj":"2199","obj":"MESH:D009369"},{"id":"A2200","pred":"tao:has_database_id","subj":"2200","obj":"MESH:D009369"},{"id":"A2201","pred":"tao:has_database_id","subj":"2201","obj":"MESH:D010146"},{"id":"A2261","pred":"tao:has_database_id","subj":"2261","obj":"MESH:D009369"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"formed an off-label trial with an association of 400–1200 mg of HCQ and a constant dose of trametinib, observing a partial response with a general reduction of tumor lesion size, circulating tumor markers and cancer-associated pain.\nIn other cancer types, such as ovar"}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T145","span":{"begin":160,"end":165},"obj":"Phenotype"},{"id":"T146","span":{"begin":191,"end":196},"obj":"Phenotype"},{"id":"T147","span":{"begin":209,"end":215},"obj":"Phenotype"},{"id":"T148","span":{"begin":227,"end":231},"obj":"Phenotype"},{"id":"T149","span":{"begin":242,"end":248},"obj":"Phenotype"}],"attributes":[{"id":"A145","pred":"hp_id","subj":"T145","obj":"http://purl.obolibrary.org/obo/HP_0002664"},{"id":"A146","pred":"hp_id","subj":"T146","obj":"http://purl.obolibrary.org/obo/HP_0002664"},{"id":"A147","pred":"hp_id","subj":"T147","obj":"http://purl.obolibrary.org/obo/HP_0002664"},{"id":"A148","pred":"hp_id","subj":"T148","obj":"http://purl.obolibrary.org/obo/HP_0012531"},{"id":"A149","pred":"hp_id","subj":"T149","obj":"http://purl.obolibrary.org/obo/HP_0002664"}],"text":"formed an off-label trial with an association of 400–1200 mg of HCQ and a constant dose of trametinib, observing a partial response with a general reduction of tumor lesion size, circulating tumor markers and cancer-associated pain.\nIn other cancer types, such as ovar"}